Prenetics Global Limited (PRE)
NASDAQ$4.25-0.1 (-2.30%)
Market Cap
$53.14M
Sector
Healthcare
Industry
Medical—Diagnostics & Research
Rank in Sector
787 of 924
Rank in Industry
43 of 49
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
PRE Insider Trading Activity
PRE Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Related Transactions
No records found
About Prenetics Global Limited
Prenetics Global Limited, an investment holding company, operates as a diagnostics and genetic testing company. Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring system that allows users to take COVID-19 tests at point-of-care or at home utilizing the nucleic acid amplification test. The company's products also comprise ColoClear, a non-invasive FIT-DNA colorectal cancer screening test; Circle SnapShot, an off-the-shelf at-home blood test; Circle Medical, a diagnostic …
Insider Activity of Prenetics Global Limited
Over the last 12 months, insiders at Prenetics Global Limited have bought $0 and sold $0 worth of Prenetics Global Limited stock.
On average, over the past 5 years, insiders at Prenetics Global Limited have bought $0 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,000 shares for transaction amount of $138,294 was made by ZWIENER DAVID K (director) on 2011‑06‑16.
List of Insider Buy and Sell Transactions, Prenetics Global Limited
| 2015-12-21 | Sale | Desmet Laurie | EVP & COO, PartnerRe Ltd | 710 0.1805% | $139.11 | $98,770 | +0.74% | |
| 2015-09-17 | Sale | SAUTTER REMY | director | 5,282 1.3362% | $138.46 | $731,338 | +0.81% | |
| 2015-09-16 | Sale | SAUTTER REMY | director | 15,613 3.9498% | $138.46 | $2.16M | +0.59% | |
| 2015-02-05 | Sale | Walker Theodore C | President & CEO, PartnerRe NA | 2,874 0.6357% | $121.06 | $347,933 | +13.82% | |
| 2014-11-28 | Sale | Clarke Emmanuel | CEO, PartnerRe Global | 500 0.107% | $117.15 | $58,575 | +12.45% | |
| 2014-10-31 | Sale | Clarke Emmanuel | CEO, PartnerRe Global | 2,000 0.4237% | $115.96 | $231,920 | +11.72% | |
| 2014-10-23 | Sale | Clarke Emmanuel | CEO, PartnerRe Global | 500 0.1051% | $115.00 | $57,500 | +13.92% | |
| 2014-09-02 | Sale | Clarke Emmanuel | CEO, PartnerRe Global | 500 0.1032% | $113.00 | $56,500 | +3.18% | |
| 2014-08-25 | Sale | Clarke Emmanuel | CEO, PartnerRe Global | 500 0.1014% | $111.00 | $55,500 | +4.72% | |
| 2014-08-25 | Sale | SAUTTER REMY | director | 5,549 1.1177% | $110.25 | $611,777 | +4.72% | |
| 2014-08-21 | Sale | SAUTTER REMY | director | 1,719 0.3463% | $110.26 | $189,545 | +5.19% | |
| 2014-08-20 | Sale | MONTUPET JEAN PAUL L | director | 2,441 0.4808% | $107.81 | $263,164 | +6.17% | |
| 2014-06-27 | Sale | Walker Theodore C | President & CEO, PartnerRe NA | 6,061 1.2% | $108.37 | $656,825 | +5.21% | |
| 2014-06-06 | Sale | Clarke Emmanuel | CEO, PartnerRe Global | 150 0.0299% | $109.12 | $16,368 | +4.03% | |
| 2014-06-05 | Sale | Clarke Emmanuel | CEO, PartnerRe Global | 500 0.0995% | $108.90 | $54,450 | +4.15% | |
| 2014-06-05 | Sale | Outtrim David | Chief Accounting Officer | 1,894 0.3745% | $108.21 | $204,955 | +4.15% | |
| 2014-05-23 | Sale | Clarke Emmanuel | CEO, PartnerRe Global | 500 0.0986% | $107.90 | $53,950 | +5.93% | |
| 2014-05-02 | Sale | Clarke Emmanuel | CEO, PartnerRe Global | 500 0.0977% | $106.90 | $53,450 | +5.83% | |
| 2014-04-29 | Sale | Clarke Emmanuel | CEO, PartnerRe Global | 200 0.039% | $106.63 | $21,326 | +6.19% | |
| 2013-12-31 | Sale | Clarke Emmanuel | CEO, PartnerRe Global | 300 0.058% | $105.90 | $31,770 | +2.61% |
Total: 115
Insider Historical Profitability
3.9%
| THIELE PATRICK A | Former Chief Executive Officer | 213446 1.7471% | $928,490.10 | 10 | 6 | +5.45% |
| ROLLWAGEN JOHN A | director | 13116 0.1074% | $57,054.60 | 1 | 26 | +7.29% |
| PABST MARK | EVP | 12069 0.0988% | $52,500.15 | 5 | 1 | +1.81% |
| ZWIENER DAVID K | director | 5587 0.0457% | $24,303.45 | 2 | 0 | <0.0001% |
Historical Insider Profitability vs. Competitors
$53,318,456 | 175 | 15.57% | $439.62M | |
$38,597,637 | 114 | 658.88% | $2.07M | |
Prenetics Global Limited (PRE) | $1,590,764 | 16 | 3.90% | $53.14M |
$26,663,659 | 7 | -12.13% | $19.78B | |
$151,252 | 6 | -58.10% | $20.14M |
PRE Institutional Investors: Active Positions
| Increased Positions | 3 | +33.33% | 27,508 | +2.47% |
| Decreased Positions | 2 | -22.22% | 364 | -0.03% |
| New Positions | 2 | New | 12,388 | New |
| Sold Out Positions | <1 | Sold Out | 114 | Sold Out |
| Total Postitions | 10 | +11.11% | 1M | +2.44% |
PRE Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Prudential Plc | $1,934.00 | 3.89% | 427,963 | 0 | 0% | 2024-12-31 |
| Aspex Management (Hk) Ltd | $1,565.00 | 3.15% | 346,150 | 0 | 0% | 2024-12-31 |
| Nomura Holdings Inc | $1,460.00 | 2.94% | 322,952 | 0 | 0% | 2024-12-31 |
| Ubs Group Ag | $125.00 | 0.25% | 27,597 | +15,120 | +121.18% | 2024-12-31 |
| Quinn Opportunity Partners Llc | $56.00 | 0.11% | 12,339 | +12,339 | New | 2024-12-31 |
| Morgan Stanley | $10.00 | 0.02% | 2,124 | -250 | -10.53% | 2024-12-31 |
| Bank Of America Corp /De/ | $1.00 | <0.01% | 111 | 0 | 0% | 2024-12-31 |
| Sbi Securities Co., Ltd. | $0 | 0% | 49 | +49 | New | 2024-12-31 |
| Wolverine Asset Management Llc | $0 | 0% | 1 | 0 | 0% | 2024-12-31 |
| Aspire Private Capital, Llc | $0 | 0% | 0 | -114 | Sold Out | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
No data is available at this moment.
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.